DeepMed Research

Shanghai Zerun Biotechnology Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Subsidiary

Established: 2003-05-07

Employees: -

Market Cap: -

Website: http://www.zerunbio.com

Clinical Trials

Long-term Follow-up of Bivalent Human Papillomavirus (HPV) Vaccine Study in Women

Active, not recruiting

Conditions: Cervical Cancer
Vulvar Cancer
Vaginal Cancer
CIN - Cervical Intraepithelial Neoplasia
Human Papillomavirus Infection

Interventions: Biological: HPV-16/18 vaccine
Biological: Placebo

First Posted Date: 2025-01-15

Last Posted Date: 2025-01-15

Lead Sponsor: Shanghai Zerun Biotechnology Co.,Ltd

Target Recruit Count: 5372

Registration Number: NCT06776055

Locations: 🇨🇳
Lingchuan Center for Disease Control and Prevention, Lingchuan, Guangxi, China
🇨🇳
Quanzhou Center for Disease Control and Prevention, Quanzhou, Guangxi, China
🇨🇳
Xing'an Center for Disease Control and Prevention, Xing'an, Guangxi, China

and more 6 locations

Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9

Phase 3

Active, not recruiting

Conditions: Genital Wart
VIN
CIN
Papillomavirus Infections
Cervical Cancer

Interventions: Biological: GARDASIL ®9
Biological: Zerun HPV-9

First Posted Date: 2022-10-14

Last Posted Date: 2022-10-28

Lead Sponsor: Shanghai Zerun Biotechnology Co.,Ltd

Target Recruit Count: 1200

Registration Number: NCT05580341

Locations: 🇨🇳
GuangXi Center for Diseases Control and Prevention, Nanning, Guangxi, China

Evaluation of Safety and Immunogenicity of the Recombinant ZR202-CoV and ZR202a-CoV Vaccines in Adults.

Phase 1

Active, not recruiting

Conditions: SARS-CoV-2 Infection
COVID-19

Interventions: Biological: ZR202a-CoV
Biological: Comirnaty®
Biological: ZR202-CoV

First Posted Date: 2022-08-05

Last Posted Date: 2023-04-20

Lead Sponsor: Shanghai Zerun Biotechnology Co.,Ltd

Target Recruit Count: 60

Registration Number: NCT05490108

Locations: 🇲🇱
Center for Vaccine Development-Mali, Bamako, Mali

Safety and Immunogenicity of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

Phase 1

Active, not recruiting

Conditions: COVID-19

Interventions: Biological: ZR-202-CoV
Other: Placebo

First Posted Date: 2022-04-06

Last Posted Date: 2023-04-19

Lead Sponsor: Shanghai Zerun Biotechnology Co.,Ltd

Target Recruit Count: 84

Registration Number: NCT05313022

Locations: 🇨🇳
Clinical Trial Institution for Anning First Hospital, Kunming, Yunan, China

Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

Phase 2

Active, not recruiting

Conditions: COVID-19

Interventions: Biological: 202-CoV standard dose
Biological: 202-CoV low adjuvant dose
Biological: 202-CoV low antigen dose
Biological: Placebo

First Posted Date: 2021-08-04

Last Posted Date: 2023-04-19

Lead Sponsor: Shanghai Zerun Biotechnology Co.,Ltd

Target Recruit Count: 528

Registration Number: NCT04990544

Locations: 🇨🇳
Xiangcheng Center for Disease Control and Prevention, Xuchang, China

Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

Phase 1

Active, not recruiting

Conditions: COVID-19

Interventions: Other: Placebo
Biological: 202-CoV low antigen dose
Biological: 202-CoV low adjuvant dose
Biological: 202-CoV standard dose

First Posted Date: 2021-07-29

Last Posted Date: 2023-04-19

Lead Sponsor: Shanghai Zerun Biotechnology Co.,Ltd

Target Recruit Count: 72

Registration Number: NCT04982068

Locations: 🇨🇳
Xiangcheng Center for Disease Control and Prevention, Xuchang, China

Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy Females

Phase 3

Completed

Conditions: HPV Infection

Interventions: Biological: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris)

First Posted Date: 2021-07-16

Last Posted Date: 2023-04-13

Lead Sponsor: Shanghai Zerun Biotechnology Co.,Ltd

Target Recruit Count: 1100

Registration Number: NCT04965350

Locations: 🇨🇳
Mianyang Center for Disease Control and Prevention, Mianyang, Sichuan, China

A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine

Phase 1

Completed

Conditions: HPV Infections

Interventions: Biological: HPV Vaccine
Drug: Placebo

First Posted Date: 2019-04-03

Last Posted Date: 2023-04-13

Lead Sponsor: Shanghai Zerun Biotechnology Co.,Ltd

Target Recruit Count: 90

Registration Number: NCT03900572

Locations: 🇨🇳
Sichuan Provincial Center for Disease Prevention and Control, Chengdu, Sichuan, China

Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females

Phase 2

Completed

Conditions: Human Papillomavirus

Interventions: Biological: HPV vaccine
Biological: Placebo

First Posted Date: 2016-04-15

Last Posted Date: 2023-04-13

Lead Sponsor: Shanghai Zerun Biotechnology Co.,Ltd

Target Recruit Count: 1200

Registration Number: NCT02740790

Locations: 🇨🇳
GuangXi Center for Diseases Control and Prevention, Nanning, Guangxi, China

Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females

Phase 2

Completed

Conditions: Human Papillomavirus
Cervical Intraepithelial Neoplasia
Persistent Infection

Interventions: Biological: HPV-16/18 vaccine

First Posted Date: 2016-04-15

Last Posted Date: 2023-04-13

Lead Sponsor: Shanghai Zerun Biotechnology Co.,Ltd

Target Recruit Count: 900

Registration Number: NCT02740777

Locations: 🇨🇳
Hezhou Center for Disease Prevention and Control, Hezhou, Guangxi, China
🇨🇳
Zhongshan Center for Disease Prevention and Control, Zhongshan, Guangxi, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy